NCT06362980View on ClinicalTrials.gov

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

PHASE1RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2026

Conditions

NSCLC

Interventions

DRUG

BPI-1178

200 or 300 mg, oral, QD

DRUG

Osimertinib

80mg, oral, QD

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center, Beijing

All Listed Sponsors

lead

National Cancer Center, China

OTHER